EMA Withdrawn: ViraferonPeg (peginterferon alfa-2b) — Merck Sharp Dohme Ltd

View source ↗

Summary

EMA has withdrawn ViraferonPeg (peginterferon alfa-2b) by Merck Sharp & Dohme Ltd for chronic hepatitis C.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ViraferonPeg (Pegylated interferon alfa-2b)

Snippet

Status: Withdrawn. Therapeutic area: Hepatitis C, Chronic. MAH: Merck Sharp Dohme Ltd. Decision date: 27/09/2018